[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "Emeryville", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 62, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 61, "title": "Co-Founder, CEO & Director", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 920970, "exercisedValue": 0, "unexercisedValue": 200938}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 60, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 678401, "exercisedValue": 0, "unexercisedValue": 4158394}, {"maxAge": 1, "name": "Dr. Noriyuki  Kasahara M.D., Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 13596, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 48, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}, {"maxAge": 1, "name": "Mr. Uneek  Mehra", "age": 51, "title": "Chief Financial & Business Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott P. Bizily J.D., Ph.D.", "age": 50, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Y. Kim M.B.A., M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.", "age": 62, "title": "Senior VP & Therapeutic Area Head of Pulmonology", "yearBorn": 1961, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 27.7, "open": 27.53, "dayLow": 26.73, "dayHigh": 27.7199, "regularMarketPreviousClose": 27.7, "regularMarketOpen": 27.53, "regularMarketDayLow": 26.73, "regularMarketDayHigh": 27.7199, "beta": 2.85, "forwardPE": -7.8823524, "volume": 107416, "regularMarketVolume": 107416, "averageVolume": 1233559, "averageVolume10days": 862770, "averageDailyVolume10Day": 862770, "bid": 26.71, "ask": 26.96, "bidSize": 100, "askSize": 100, "marketCap": 1334052992, "fiftyTwoWeekLow": 9.44, "fiftyTwoWeekHigh": 36.25, "priceToSalesTrailing12Months": 64.37547, "fiftyDayAverage": 28.6762, "twoHundredDayAverage": 18.818525, "currency": "USD", "enterpriseValue": 1511980416, "floatShares": 31138707, "sharesOutstanding": 49778100, "sharesShort": 8500234, "sharesShortPriorMonth": 7061371, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.1708, "heldPercentInsiders": 0.03632, "heldPercentInstitutions": 0.87711996, "shortRatio": 10.54, "shortPercentOfFloat": 0.2134, "impliedSharesOutstanding": 49778100, "bookValue": 7.146, "priceToBook": 3.7503498, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -100837000, "trailingEps": -2.58, "forwardEps": -3.4, "pegRatio": 0.57, "enterpriseToRevenue": 72.961, "enterpriseToEbitda": -13.914, "52WeekChange": 0.7130488, "SandP52WeekChange": 0.2565279, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FDMT", "underlyingSymbol": "FDMT", "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "firstTradeDateEpochUtc": 1607697000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3c71667a-4f1e-3d28-8cb0-26ab7aa9e925", "messageBoardId": "finmb_272879653", "gmtOffSetMilliseconds": -14400000, "currentPrice": 26.8, "targetHighPrice": 82.0, "targetLowPrice": 34.0, "targetMeanPrice": 52.44, "targetMedianPrice": 45.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 288232000, "totalCashPerShare": 5.79, "ebitda": -108663000, "totalDebt": 14671000, "quickRatio": 15.209, "currentRatio": 15.65, "totalRevenue": 20723000, "debtToEquity": 4.766, "revenuePerShare": 0.53, "returnOnAssets": -0.23446, "returnOnEquity": -0.37405, "freeCashflow": -46483876, "operatingCashflow": -75792000, "grossMargins": 0.52999, "operatingMargins": 1929.0526, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-12"}]